Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0738 | 0.0738 |
Schistosoma mansoni | vesicular amine transporter | 0.0273 | 0.8997 | 0.9847 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Echinococcus multilocularis | roundabout 2 | 0.0277 | 0.9136 | 1 |
Brugia malayi | Fibronectin type III domain containing protein | 0.0277 | 0.9136 | 0.9136 |
Schistosoma mansoni | cell adhesion molecule | 0.0277 | 0.9136 | 1 |
Schistosoma mansoni | defective proboscis extension response (dpr)-related | 0.0273 | 0.8997 | 0.9847 |
Schistosoma mansoni | nephrin | 0.0277 | 0.9136 | 1 |
Schistosoma mansoni | Neurotrimin precursor (hNT) | 0.0273 | 0.8997 | 0.9847 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0738 | 0.0738 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.9136 | 0.9136 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0299 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.9136 | 0.9136 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Brugia malayi | hypothetical protein | 0.0277 | 0.9136 | 0.9136 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0738 | 0.0738 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0738 | 0.0738 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0277 | 0.9136 | 0.9136 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.9136 | 0.9136 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.8997 | 0.8997 |
Echinococcus granulosus | roundabout 2 | 0.0277 | 0.9136 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.9811 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.